Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer

The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. In particular, approximately 30%–40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.

[1]  Laurence Collette,et al.  Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.

[2]  O. Delattre,et al.  Survival and acquired genetic alterations in colorectal cancer. , 1992, Gastroenterology.

[3]  S. Bettelli,et al.  Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy , 2010, British Journal of Cancer.

[4]  S. Rodenhuis,et al.  Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver , 1991, International journal of cancer.

[5]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[6]  M. Morrin,et al.  Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. , 1994, Gut.

[7]  A. Bardelli,et al.  Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer , 2009, Journal of the National Cancer Institute.

[8]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[9]  H. Ludwig,et al.  The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer , 1993, Cancer.

[10]  Ronald Abraham,et al.  Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. , 2010, The Journal of molecular diagnostics : JMD.

[11]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[12]  Karin Haustermans,et al.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. , 2010, The Lancet. Oncology.

[13]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[14]  R. Vyzula,et al.  Altered Expression of miR-21, miR-31, miR-143 and miR-145 Is Related to Clinicopathologic Features of Colorectal Cancer , 2008, Oncology.

[15]  M. Stratton,et al.  Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. , 1989, Cancer research.

[16]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[17]  J. Horiot,et al.  Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group. , 1993, European journal of cancer.

[18]  A. Bardelli,et al.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.

[19]  V. Catalano,et al.  Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan , 2010, The Pharmacogenomics Journal.

[20]  G. Capellá,et al.  Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. , 1991, Environmental health perspectives.

[21]  G. Taylor,et al.  Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. , 1993, Gastroenterology.

[22]  B. Iacopetta,et al.  The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short‐term prognostic indicators of survival , 1994, International journal of cancer.

[23]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  I. Floriani,et al.  High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. , 2008, The oncologist.

[25]  Y. Akao,et al.  Role of anti-oncomirs miR-143 and -145 in human colorectal tumors , 2010, Cancer Gene Therapy.

[26]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[27]  Ju-Seog Lee,et al.  LIN28B promotes colon cancer progression and metastasis. , 2011, Cancer research.

[28]  D. Huhn,et al.  Position specificity of Ki-ras oncogene mutations during the progression of colorectal carcinoma. , 1993, Oncology.

[29]  E. Van Cutsem,et al.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  H. Samonigg,et al.  Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer , 2012, British Journal of Cancer.

[31]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Y. Toiyama,et al.  The prognostic value of KRAS mutations in patients with colorectal cancer. , 2012, Oncology reports.

[33]  C. Bokemeyer,et al.  Kras mutations and outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab , 2011 .

[34]  M. Lea.  Recently identified and potential targets for colon cancer treatment. , 2010, Future oncology.

[35]  S. Finkelstein,et al.  Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K‐ras‐2 mutation type , 1993, Cancer.

[36]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  O. Kranenburg,et al.  The KRAS oncogene: past, present, and future. , 2005, Biochimica et biophysica acta.

[38]  Y. Akao,et al.  let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. , 2006, Biological & pharmaceutical bulletin.

[39]  N. Kemeny,et al.  KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases , 2010, Annals of Surgical Oncology.

[40]  L. Terracciano,et al.  Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer , 2010, International journal of cancer.

[41]  K. Bland,et al.  Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. , 1995, American journal of surgery.

[42]  H. Lee,et al.  Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer , 2012, BMC Cancer.

[43]  B. Vogelstein,et al.  Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.

[44]  Larissa V Furtado,et al.  Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer , 2011, Genes, chromosomes & cancer.

[45]  W. Park,et al.  LIN28B confers radio-resistance through the posttranscriptional control of KRAS , 2009, Experimental & Molecular Medicine.

[46]  A. Rustgi,et al.  LIN28B fosters colon cancer migration, invasion, and transformation through let-7 dependent and independent mechanisms , 2011, Oncogene.

[47]  S. Söldner-Rembold,et al.  The first 30 years , 1983 .

[48]  Jun Yu,et al.  MicroRNA in colorectal cancer: from benchtop to bedside. , 2011, Carcinogenesis.

[49]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[50]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[51]  N. Goldstein,et al.  Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.

[52]  Sabine Tejpar,et al.  Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.

[53]  L. Loeb,et al.  Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[54]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[55]  C. Bokemeyer,et al.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  H. Rabes,et al.  K‐ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis , 1992, International journal of cancer.

[57]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[58]  P. Seeburg,et al.  Biological properties of human c-Ha-ras1 genes mutated at codon 12 , 1984, Nature.

[59]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[60]  C. Der,et al.  Understanding Ras: 'it ain't over 'til it's over'. , 2000, Trends in cell biology.

[61]  X. Chen,et al.  Role of miR-143 targeting KRAS in colorectal tumorigenesis , 2009, Oncogene.

[62]  Jia Yu,et al.  miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. , 2010, Cancer research.

[63]  C. Kittas,et al.  K-ras mutation in Greek patients with poorly and moderately differenciated tumours of the lower intestinal tract. , 1997, Anticancer research.

[64]  C. Steer,et al.  MicroRNA‐143 reduces viability and increases sensitivity to 5‐fluorouracil in HCT116 human colorectal cancer cells , 2009, The FEBS journal.

[65]  S. Rodenhuis,et al.  Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.

[66]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[68]  C. Bokemeyer,et al.  Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  R. Greil,et al.  Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group , 2012, BMC Cancer.

[70]  R. Weinberg,et al.  Activation of Ha-ras p21 by substitution, deletion, and insertion mutations , 1985, Molecular and cellular biology.

[71]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[72]  C. Der,et al.  Inhibition of Ras for cancer treatment: the search continues. , 2011, Future medicinal chemistry.

[73]  William E. Grizzle,et al.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis , 1987, Nature.

[74]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[75]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[76]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[77]  V. Ambros.  microRNAs Tiny Regulators with Great Potential , 2001, Cell.

[78]  K. Omura,et al.  Prognostic factors of colorectal cancer: K‐ras mutation, overexpression of the p53 protein, and cell proliferative activity , 1994, Journal of surgical oncology.

[79]  N. Quenville,et al.  Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki‐67 , 1992, Journal of surgical oncology.

[80]  C. Tournigand,et al.  Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma , 2001, Cancer.